The U.S. Environmental Protection Agency is under a congressional mandate to revise its current standard for arsenic in drinking water. We present a risk assessment for cancers of the bladder, liver, and lung from exposure to arsenic in water, based on There has been substantial focus on the association between arsenic and skin cancer, and there is also substantial evidence that exposure to arsenic in drinking water increases the mortality risk for several internal cancers. Increases in bladder and lung cancer mortality were found in a region of northern Chile (6). An association was also found between bladder cancer mortality and arsenic in drinking water in Argentina (7). Significant increased mortality was observed for males and females in Taiwan due to lung, liver, skin, kidney, and bladder cancer (8). The National Research Council presents a more detailed summary of the evidence linking arsenic exposure to internal cancer (1).
A metal found in rocks and mineral formations in the earth's crust, arsenic has long been associated with the development of cancer in humans. Exposure (1) . In a 1984 health assessment, the U.S. Environmental Protection Agency (EPA) dassified arsenic as a dass A human carcinogen, based primarily on epidemiologic evidence, and produced quantitative risk estimates for both ingestion and inhalation routes of exposure (2) . Although the EPA assessment for the inhalation route is well accepted, the risk assessment for ingestion remains controversial. The 1984 risk assessment for arsenic in drinking water was based on an epidemiologic study in Taiwan that examined an association between arsenic exposure via drinking water and skin cancer (nonmelanoma) (3) . EPA investigators estimated that the lifetime risk of skin cancer for individuals who consumed 2 L water per day at 50 psg/L could be as high as 2 in 1,000. This high value prompted questions about the 1984 risk assessment, including applicability of the risk assessment to the U.S. population, the role of arsenic as an essential nutrient, the relevance of skin lesions as the basis for the risk assessment, and the role of arsenic intake via food. In 1988, the EPA Risk Assessment Forum published a revised skin cancer risk assessment and focused attention on these questions (4) . The EPA is currently under a congressional mandate to finalize a new rule for arsenic in drinking water by 1 January 2001 (5) .
There has been substantial focus on the association between arsenic and skin cancer, and there is also substantial evidence that exposure to arsenic in drinking water increases the mortality risk for several internal cancers. Increases in bladder and lung cancer mortality were found in a region of northern Chile (6) . An association was also found between bladder cancer mortality and arsenic in drinking water in Argentina (7) . Significant increased mortality was observed for males and females in Taiwan due to lung, liver, skin, kidney, and bladder cancer (8) . The National Research Council presents a more detailed summary of the evidence linking arsenic exposure to internal cancer (1) .
The purpose of this article is to present a risk assessment for mortality due to several internal cancers based on a reanalysis of the data reported by Chen et al. (8) . Brown (9) discussed the limitations of the data available for analysis when the current EPA risk assessment (4) was prepared. For several reasons, it can be argued that the risk assessment of internal cancers presented in this paper yields more convincing results than the previous EPA assessment based on skin cancer. First, the current study focuses on mortality from bladder, lung, and liver cancers identified through national death records. In addition, unlike the Tseng et al. (3) study that was used in the EPA analysis, which grouped data into three broad exposure intervals [low (< 300 pg/L), medium (300-600 pg/L), and high (> 600 pg/L)], data now available provide exposure at the individual village level.
This paper is a follow-up to a preliminary study that focused only on bladder cancer and examined model sensitivity (10) . The current analysis is expanded to include lung and liver cancers and examines issues of dose-response modeling by Poisson regression, in addition to application of the multistage-Weibull (MSW) model, in more detail.
Materials and Methods
Internal cancer data. Data used in this analysis were derived from a study in an arseniasis-endemic area of Taiwan (11) (12) (13) . Cancer mortality data were collected from death certificates of residents of 42 villages during [1973] [1974] [1975] [1976] [1977] [1978] [1979] [1980] [1981] [1982] [1983] [1984] [1985] [1986] (14) . The (12) . The artesian wells were gradually closed; the last one dosed in mid-1970. Although mortality data were collected for a later time period (1973) (1974) (1975) (1976) (1977) (1978) (1979) (1980) (1981) (1982) (1983) (1984) (1985) (1986) , it is likely that arsenic levels in well water remained relatively unchanged over this time period. It could also be argued that because of the long latency of the cancers of interest, it is appropriate for exposure to be based on a time period 10 (18) . The latter is expected to provide a more suitable comparison basis for the study population, which is largely rural and fairly poor. (17) . In our analysis, we assumed that the number of deaths due to cancer follows a Poisson distribution with parameter equal to the person-years at risk multiplied by the hazard of dying of cancer. The hazard is often modeled as a function of age (t) and exposure (x). As described by Breslow and Day (17) , a broad class of models can be characterized using the following general form, h(x,t) = ho(t) X g(x), [1] where h0 (4 Table 1 ). The third option can be accomplished by fitting a Poisson model containing indicators corresponding to the age categories observed in the comparison population. This approach essentially corresponds to the traditional SMR approach. Because there were no villages with zero concentration levels, the method used to model the baseline hazard had a fairly strong influence on the results. In particular, the choice of whether to include a comparison population had a strong influence. The use of an unexposed comparison population has the potential to provide more information about the shape of the model at low concentrations.
Although not a member of the usual GLM class, the MSW model was also considered because it was used in the previous risk assessment (4) . The MSW corresponds to letting g(x) = PO + IX + 2x2 and ho(t) = C(t-To)+ (10) , where tdenotes age and x denotes exposure concentration. The plus sign (+) indicates a truncation on the (t -To) term (i.e., if To > t then the term is set to zero). Results based on the MSW model are only presented for comparison. The GLM approach has several advantages over the MSW model. First, the MSW model appears to be more sensitive to outliers than the GLM model (1J). Also, the hazard function for the MSW model involves a truncation in t that complicates estimation. Finally, the inclusion of the power parameter k (for our purposes, k = 2) tends to give the fitted model a relatively sublinear shape that leads, adding twice the number of parameters to it. Thus a model with a low AIC will be one that describes the observed data well (a low deviance) yet with relatively few parameters (small penalty). The models with the lowest AIC provide the best fit. Because it was not appropriate to compare AIC for the models based on different data sets, we provide separate analyses with and without comparison populations. Table 6 identifies models 1-9 and the MSW model that appear in Tables 7-10 and Figures 1-3 . For simplicity we will refer to the model numbers. Table 7 Table 6 . of models, see (10) , one possible explanation is the uncertainty associated with an ecologic study design. We assumed the same arsenic concentration for all persons in the same village and individual exposures can vary widely in a village. Mortality records are available for individuals, but their individual exposures are not. The National Academy of Sciences (1) provides a good discussion on this subject.
Although one might argue that the appropriate strategy would be to select the best model based on accepted statistical criteria, several models gave essentially the same quality fit (as measured by AIC), yet yielded substantial differences in risk estimates. For example, for the models without a comparison population, the MSW model gave a fit comparable to some of the GLM models, but produced EDOI estimates almost twice as high. Despite the comparably good fit, we preferred the GLM models to the MSW model. For example, sensitivity analysis revealed that the MSW model was influenced strongly by the removal of various subsets of villages, whereas the GLM was not (10) . The poor nutritional status of the Taiwanese in the Blackfoot disease region could be another contributing factor of uncertainty. We could not account for dietary intake of inorganic arsenic in food for either population, or for other confounders in this analysis.
Differences in EDOI estimates were particularly affected by whether or not a comparison population was used. There is reason to believe that the urban Taiwanese population is not a comparable population for the poor rural population used in this study. Thus, risk estimates using the Taiwanese population may be biased. As an alternative, we used the southwestern region of Taiwan; we found very different risk estimates based on the two different comparison populations (Tables 9 and 10 
